Considerations in Managing Major Depressive Disorder in Patients With Comorbid Cardiovascular Disease
|
|
- Hubert Bradford
- 6 years ago
- Views:
Transcription
1 Considerations in Managing Major Depressive Disorder in Patients With Comorbid Cardiovascular Disease Otsuka Pharmaceutical Development & Commercialization, Inc. Lundbeck, LLC 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD. July 2017 MRC2.CORP.D advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
2 Sloan Manning, MD Medical Director Novant Health Urgent Care & Occupational Medicine Adjunct Associate Professor University of North Carolina School of Medicine Co-Director of the Mood Disorder Clinic Moses Cone Family Medicine Residency Program Madhukar Trivedi, MD Director of Mood Disorders Research Professor UT Southwestern Medical Center Betty Jo Hay Distinguished Chair in Mental Health Julie K. Hersh Chair for Depression Research and Clinical Care 2
3 This presentation was developed with the support of Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and Lundbeck, LLC Drs Manning and Trivedi are compensated contractors of OPDC 3
4 PsychU Virtual Forum: Rules of Engagement Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and Lundbeck, LLC have collaborated with OPEN MINDS to explore new ways of bringing and increasing awareness of serious mental illness OPDC/Lundbeck s interaction with OPEN MINDS is through PsychU, an online, non-branded portal dedicated to providing information and resources on important disease state and care delivery topics related to mental illness. A method that will be employed for the sharing of information is the hosting of virtual fora. Virtual fora conducted by OPDC/Lundbeck are based on the following parameters: When conducting medical dialogue, whether by presentation or debate, OPDC/Lundbeck and their paid consultants aim to provide the viewer with information that is accurate, not misleading, scientifically rigorous, and not a promotion of OPDC/Lundbeck products OPDC/Lundbeck and their paid consultants do not expect to be able to answer every question or comment during a PsychU Virtual Forum; however, they will do their best to address important topics and themes that arise OPDC/Lundbeck and their paid consultants are not able to provide clinical advice or answer questions related to specific patients conditions Otsuka and Lundbeck employees and contractors should not participate in this program (eg, submit questions or comments) unless they have received express approval to do so from Otsuka Legal Affairs. OPDC/Lundbeck operate in a highly regulated and scrutinized industry. Therefore, we may not be able to discuss every issue or topic that you are interested in, but we will do our best to communicate openly and directly. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind. 4
5 Key Objectives Describe the bidirectional association between major depressive disorder and cardiovascular disease Review pathophysiology that may underlie the complex relationship between cardiovascular disease and depression Discuss considerations for pharmacological treatment of depression that avoid exacerbation of cardiovascular symptoms Discuss nonpharmacological considerations for patients with depression and comorbid cardiovascular disease 5
6 Bidirectional Relationship Between Major Depressive Disorder (MDD) and Cardiovascular Disease (CVD) advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
7 Depression and Cardiovascular Disease: A Bidirectional, Multifaceted Relationship Depressi on Depression doubles the risk of developing new cardiovascular disease 1 and may be associated with greater cardiac Text complications 2 Depression is 3 times more frequent in patients after an acute MI than in the general community and may be associated with worse prognosis 3 MI, myocardial infarction. 1. Hare et al. Eur Heart J. 2014;35: Khawaja et al. Psychiatry 2009;6: Lichtman et al. Circulation. 2008;118:
8 Depression Is Highly Prevalent in Patients With Cardiovascular Disease After acute myocardial infarction, two-thirds of patients reported mild depression 1 Approximately 15% of patients with CVD had MDD (2 to 3 times higher than the general population) 1 40% of patients with severe chronic heart failure (NYHA class IV) were depressed 3 27% of patients undergoing coronary artery bypass graft surgery had depression afterwards 2 CVD, cardiovascular disease; MDD, major depressive disorder; NYHA, New York Heart Association. 1. Hare et al. Eur Heart J. 2014;35: Khawaja et al. Psychiatry 2009;6: Rutledge et al. J Am Coll Cardiol 2006;48:
9 Patients With Major Depressive Disorder Demonstrated Reduced Cardiac Resilience Decreased heart rate variability (HRV) Marker of autonomic inflexibility, inability to respond to change, and ill health 1 May be a trait marker for depression 2 May link cardiovascular disease, depression, and sudden cardiac death 2 Patients with depression with comorbid cardiovascular disease displayed lower HRV than patients who were not depressed 1 Unmedicated patients with major depressive disorder and no cardiovascular disease displayed lower HRV than healthy, age-matched controls 1 Low HRV predicts Future adverse cardiovascular events 2 Inflammatory-mediated atherosclerosis 1 Death after myocardial infarction 2 1. Kemp et al. PLOS One. 2012;7:e Brunoni et al. Int J Neuropsychopharmacol. 2013;16:
10 Depression and Cardiovascular Disease Comorbidity Is Associated With Poor Outcomes After myocardial infarction, patients with depression had More medical comorbidities and cardiac complications 1 3-fold increase in mortality 2 41% higher 1-year health costs 1 Negative outcomes associated with comorbidity 1,2 Patients with acute coronary syndrome and history of depression reported 1 Triple the physical limitations Almost triple the risk of diminished health-related quality of life Twice the rate of angina Patients with chronic heart disease and depression reported 1 Depression as the most important correlate of diminished quality of life More days in bed due to illness More ambulatory and emergency room visits Increased functional disability 1. Davidson. ISRN Cardiology. 2012;2012: Hare et al. Eur Heart J. 2014;35:
11 Depression Is a Predictor of Mortality in Patients With Established Coronary Heart Disease In patients with established CHD, depression was predictive of all-cause mortality and cardiac-related mortality 1 Studies analyzed Van Melle et al, 2004 Outcome(s) assessed All-cause mortality Cardiac mortality Cardiovascular events OR relative risk (95% CI) of CHD P value < < < Barth et al, 2004 All-cause mortality NR Nicholson et al, 2006 All-cause mortality < Meijer et al, 2011 Meijer et al, 2013 All-cause mortality Cardiac mortality Cardiovascular events All-cause mortality Cardiovascular events <0.001 <0.001 <0.001 <0.001 < Following a meta-analysis of 53 studies, an AHA expert panel recommended that depression be elevated to the status of a risk factor for poor prognosis in patients with ACS 2 ACS, acute coronary syndrome; AHA, American Heart Association; CHD, coronary heart disease; CI, confidence interval; NR, not reported; OR, odds ratio. 1. Carney and Freedland. Nat Rev Cardiol. 2017;14: Lichtman et al. Circulation. 2014;129:
12 Pathophysiology Underlying Major Depressive Disorder and Cardiovascular Disease advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
13 Psychosocial Factors May Negatively Affect Select Biological Mechanisms Mood state (eg, depression, anxiety) can lead to increased Inflammation Platelet function Autonomic nervous system dysregulation Hypothalamic pituitary adrenal axis dysregulation Acute stress (eg, traumatic life event) can lead to increased Sympathetic nervous system function Hypothalamic pituitary adrenal axis activity Blood pressure Heart rate Interleukin-6 level Chronic stress (eg, work stress, marital strain, life adversity) can lead to increased Sympathetic nervous system function Hypothalamic pituitary adrenal axis activity Ambulatory blood pressure Heart rate Inflammation Stoll et al. J Cardiovasc Dis Diagn. 2014;2:
14 Complex Relationship Between Depression and Cardiovascular Disease 1 Psychosocial stress can lead to chronic inflammation throughout the body, contributing to both depression 2 and cardiovascular disease 3 Depression Biological mechanisms influence both depression and cardiovascular disease 1 eg, inflammation, autonomic nervous system, platelet receptors, coagulopathic factors, endothelial function, neurohormonal factors, and genetic linkages such as serotonin transporter mechanism Cardiovascular disease Depression may lead to behavioral factors that facilitate development of cardiovascular disease 4 eg, weight gain, inactivity, poor nutrition Perceived loss (eg, perception of lost independence or physical health) can lead to a depressed state 1 1. Hare et al. European Heart Journal. 2014;35: Miller et al. Nat Rev Immunol. 2016;16: Puzianowska-Kuźnicka et al. Immun Ageing. 2016;13: Crichton et al. BMC Public Health. 2016;16:
15 Inflammation Plays a Key Role in Both Depression and Cardiovascular Disease Patients with depression display higher levels of the inflammatory cytokines IL-6 and TNF-α 1 Relative risk of recurrent myocardial infarction or coronary death is elevated in patients with higher baseline levels of C-reactive protein 2 IL Healthy controls MDD patients TNF-ɑ Healthy controls MDD patients CRP, C-reactive protein; IL-6, interleukin 6; MDD, major depressive disorder; TNF-α, tumor necrosis factor alpha. *P<0.05 vs <0.12 mg/dl CRP. 1. Kim et al. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31: Ridker et al. Circulation. 1998;98: Relative risk of MI or coronary death * <0.12 >0.66 Baseline CRP (mg/dl) 15
16 Microbiota-Gut-Brain Axis May Link Depression and Comorbidities 1,2 The gut microbiome is influenced by diet, may be associated with the pathogenesis of MDD and other conditions, and may contribute to drug metabolism and interindividual variability in treatment efficacy and side effects 2 MDD Obesity Type 2 diabetes Chronic fatigue syndrome IBS Excess inflammation Unhealthy diet Healthy diet Healthy CNS function Healthy levels of inflammatory cells Short-chain fatty acids Serotonin Dysbiosis (microbial imbalance in the gastrointestinal tract) Eubiosis (Healthy balance of microflora in the gastrointestinal tract) CNS, central nervous system; IBS, irritable bowel syndrome MDD, major depressive disorder. 1. Slyepchenko et al. Psychother Psychosom. 2017;86: Rogers et al. Molecular Psychiatry. 2016;21:
17 Considerations for Management of Depression in Patients With Comorbid Cardiovascular Disease advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
18 Routine Depression Screening Is Recommended for Patients With Coronary Heart Disease The AHA and APA suggest screening for depressive symptoms in patients with CHD to identify patients who may require further assessment and treatment 1. Screen with PHQ-2 2. Screen with PHQ-9 If yes to either question If necessary, evaluate for acute suicidality and respond accordingly Minimal symptoms, short duration Mild to moderate, uncomplicated Major depression Provide support and education follow-up If symptoms persist or worsen Refer for clinical evaluation by mental health specialist Determine appropriate treatment and carefully monitor for adherence, drug efficacy, and safety AHA, American Heart Association; APA, American Psychiatric Association; CHD, coronary heart disease; PHQ, Patient Health Questionnaire. Lichtman et al. Circulation. 2008;118:
19 Optimal Treatment for Depression May Involve a Combination of Approaches Although antidepressants are the cornerstone of treatment for depression, a combination of treatments may yield optimal outcomes Pharmacotherapy Antidepressants Atypical antipsychotics Lithium Thyroid medication L-methylfolate Psychostimulants Sedative-hypnotic medications Psychotherapy CBT Individual therapy Group therapy Problem-solving therapy Other Electroconvulsive therapy TMS VNS Light therapy Promotion of healthy behaviors Sleep hygiene Decreased caffeine, tobacco, and alcohol Increased exercise Weight loss Meditation CBT, cognitive-behavioral therapy; TMS, transcranial magnetic stimulation; VNS, vagus nerve stimulation. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Major Depressive Disorder. 3rd ed
20 Antidepressants Have Been Associated With Weight Gain and Metabolic Abnormalities Weight gain is a common side effect of acute and long-term antidepressant use 1 TCAs and MAOIs are more likely to cause weight gain than SSRIs Antidepressant use may be associated with 2 Metabolic syndrome Metabolic syndrome components * 2.01* 1.99* Metabolic syndrome HDL, high-density lipoprotein MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. *P<0.01 vs patients not using antidepressants. P< Fava. J Clin Psychiatry. 2006;61(Suppl11): Crichton et al. BMC Public Health. 2016;16:502. Odds ratio Odds of metabolic syndrome and individual syndrome components in patients with depression (Maine-Syracuse Longitudinal Study) 2 Elevated glucose No antidepressant use Hypertension 1.66 Low HDL cholesterol Antidepressant use 20
21 Cardiovascular Side Effects of Antidepressants Examples of cardiovascular side effects of antidepressants 1,2 Lengthening of cardiac myocyte action potentials Increases in heart rate Increases in blood pressure Orthostatic hypertension Arrhythmias Tachycardia Hypertensive crisis Tricyclic antidepressants and monoamine oxidase inhibitors are contraindicated in many patients with comorbid cardiac conditions because they may cause cardiotoxic side effects 3 Determining optimal therapy for patients with chronic heart failure may be challenging. For example, when the QTc interval is borderline, the physician may choose to examine the potential for improved quality of life against potential arrhythmic risk 1 1. Hare et al. Eur Heart J. 2014:35: American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Major Depressive Disorder. 3rd ed Lichtman et al. Circulation. 2008;118:
22 SSRI Treatment Can Improve Global Functioning in Patients With MDD and Are Generally Safe in the Cardiac Setting CGI-I responders, % Treatment with an SSRI significantly improved CGI-I score vs placebo in patients with recurrent depression with recent MI or unstable angina (SADHART trial) * SSRI 51 Patients with any recurrent MDD Placebo 78 78* 45 Patients with severe MDD No significant difference between groups in measures of cardiovascular safety LVEF Heart rate Blood pressure PR interval QRS duration QTc interval Measure of autonomic balance Ventricular tachycardia Laboratory indices CGI-I, Clinical Global Impression Improvement scale; LVEF, left ventricular ejection function; MDD, major depressive disorder; MI, myocardial infarction; PR interval, time from the onset of the P wave to the start of the QRS complex; QRS complex, the portion of the electrocardiogram comprising the Q, R, and S waves, together representing ventricular depolarization; QTc interval, corrected measure of the time between the start of the Q wave and the end of the T wave; SSRI, selective serotonin reuptake inhibitor. *P<0.01 vs placebo. 1. Glassman et al. JAMA; 2002;288:
23 Inflammation May Influence Effectiveness of Antidepressant Treatment CRP levels have been differentially related to antidepressant treatment outcomes in patients with MDD 1 Remission rate 1 Reduction in disease severity over time 1 SSRI n=51 NDRI + SSRI n=55 Remission during acute phase of CO-MED, % CRP< 1mg/L CRP 1mg/L QIDS-SR score, mean * * * SSRI CRP <1 mg/l SSRI CRP 1 mg/l NDRI + SSRI CRP <1 mg/l NDRI + SSRI CRP 1 mg/l * Week Data are consistent with a previous assessment of patients with depression 2 in which Patients with CRP <1 mg/l had greater reduction in depression severity with an SSRI (compared with a TCA) Patients with CRP 1 mg/l had better response to a TCA (compared with an SSRI) CO-MED, Combining Medications to Enhance Depressions Outcome; CRP, C-reactive protein; MDD, major depressive disorder; NDRI, norepinephrinedopamine reuptake inhibitor; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. *P 0.05 for SSRI CRP <1 vs 1 mg/l. 1. Jha et al. Psychoneuroendocrinology. 2017;78: Uher et al. Am J Psychiatry. 2014;171:
24 Adjunctive Treatment Options in Patients With Inadequate Response to Antidepressive Treatment Adjunctive atypical antipsychotics may improve rate of remission Studies analyzed* Shelton et al Shelton et al Corya et al Thase et al. I 2007 Thase et al. II 2007 Mahmoud et al Keitner et al Reeves et al Khullar et al Mattingly et al McIntyre et al Earley et al El-Khalili et al Berman et al Berman et al Marcus et al Odds ratio, 95% CI Individual patient characteristics and relative risk of side effects should inform optimal treatment choice Favors placebo Favors atypical antipsychotics CI, confidence interval. *Meta-analysis of 16 trials in patients with treatment-resistant major depressive disorder (N=3484 patients). Nelson and Papakostas. Am J Psychiatry. 2009;166:
25 Nonpharmacological Considerations for Depression and Cardiovascular Disease advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
26 Many Guidelines Recommend Nonpharmacological Interventions for MDD and CV Risk Reduction In addition to recommending pharmacological therapy, treatment guidelines for MDD 1 and reduction of CV risk 2 promote healthy behaviors Healthy weight Physical activity Good nutrition Psychosocial interventions Cessation of smoking or substance use Establish a therapeutic alliance CV, cardiovascular; MDD, major depressive disorder. 1. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Major Depressive Disorder. 3rd ed Eckel et al. J Am Coll Cardiol. 2014;63:
27 Weight Management May Help Optimize MDD Treatment and Reduce Cardiovascular Risk Patients with MDD and elevated BMI demonstrated a reduced rate of response with antidepressants 1 Patients with >50% reduction in HAM-D score after 5 weeks, % Normal weight (BMI 25) 46.5 Overweight (BMI >25 and 30) 17.4 Obese (BMI >30) For all patients, including those with mental illness, as little as 5% weight loss may significantly decrease risk factors of cardiometabolic disease, including 2 Glucose Glycemic control Triglycerides HDL cholesterol Blood pressure BMI, body mass index; HAM-D, Hamilton Rating Scale for Depression; HDL, high-density lipoprotein; MDD, major depressive disorder. 1. Kloiber et al. Biol Psychiatry. 2007;62: Wing et al. Diabetes Care. 2011;34:
28 Physical Activity May Improve Depression and Cardiovascular Health Patients with inadequate response to SSRI who added exercise demonstrated improved rates of remission after 12 weeks 1 50 In patients with recent AMI, exercise reduced rate of mortality and subsequent nonfatal AMI over 4 years Patients, % * Patients, % Low add-on exercise 4 kcal/kg/wk (n=61) High add-on exercise 16 kcal/kg/wk (n=61) AMI, acute myocardial infarction; SSRI, selective serotonin reuptake inhibitor. *P<0.05 vs low add-on exercise. 1. Trivedi et al. J Clin Psychiatry. 2011;72: Blumenthal et al. Med Sci Sports Exerc. 2004;36: Mortality (all cause) Patients reporting regular exercise Subsequent AMI (nonfatal) Patients reporting no regular exercise 28
29 Interventions That Decrease Psychosocial Stress May Improve Life Expectancy In female patients hospitalized for coronary disease,* adding a psychosocial intervention to treatment regimen was associated with a reduction in all-cause mortality Cumulative all-cause mortality, % Women receiving usual care (n=125) Women receiving usual care and psychosocial intervention (n=112) Year after hospitalization *Women (N=237) were consecutively hospitalized at a university hospital in Stockholm, Sweden, for acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention. Patients were not screened at enrollment for depression. Intervention provided education about the heart, achieving a healthy lifestyle, improving mastery of marital stress, coping with illness, counteracting anxiety and depression, improving social relationships, and relaxation. Orth-Gomer et al. Circ Cardiovasc Qual Outcomes. 2009;2: % 7.1% ~3-fold protective effect of adding intervention 29
30 Healthy Lifestyle Modifications May Improve Overall Wellness Intensive lifestyle modifications* improved cardiovascular risk factors, as well as ratings of depression, physical health, and mental health, over a 1-year period 50 Body mass index LDL cholesterol (mg/dl) Total cholesterol (mg/dl) Depression scale (CES-D) Physical health composite Mental health composite 36.8 Change from baseline, % Patients with cardiovascular disease (N=35) Patients with elevated risk factors (N=37) LDL, low-density lipoprotein; CES-D, Center for Epidemiologic Studies Depression Scale. *Program includes eating a low-fat vegetarian diet, participating in 1 hour of stress management per day, performing 3 hours of aerobic exercise each week, and attending weekly group support sessions for 1 year. Participants must have a diagnosis of cardiovascular disease or two or more cardiovascular risk factors and were not screened for depression before enrollment. Ellsworth et al. Prev Cardiol. 2004;7:
31 Summary Major depressive disorder (MDD) and cardiovascular disease are highly comorbid and share a complex, multifactorial, and bidirectional relationship Psychosocial, biological, and behavioral mechanisms may underlie the shared pathophysiology between MDD and cardiovascular disease Individual patient characteristics and possible adverse effects are factors in treatment choice for patients with comorbid MDD and cardiovascular disease Nonpharmacological strategies, such as increasing physical activity, may confer benefit in patients with comorbid MDD and cardiovascular disease 31
32 Discussion advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
33 Thank You advice or professional diagnosis. Users seeking medical advice should consult with their physician or other healthcare professional.
Depression in Peripheral Artery Disease: An important Predictor of Outcome. Goals. Goals. Marlene Grenon, MD Assistant Professor of Surgery, UCSF
Depression in Peripheral Artery Disease: An important Predictor of Outcome There are no conflicts of interest Marlene Grenon, MD Assistant Professor of Surgery, UCSF UCSF VASCULAR SURGERY SYMPOSIUM SAN
More informationSuboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies
Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,
More informationDiabetes. & Mental Health. David J. Robinson MD, FRCPC. This slide is for review purposes only and not for presentations.
Diabetes This slide is for review purposes only and not for presentations & Mental Health David J. Robinson MD, FRCPC CMHA - London, ON In the past 2 years, I have received speaking honoraria from, and
More informationExploring Nonpharmacological Anti-inflammatory Strategies in Mental Health: Connecting Science to Clinical Practice
Exploring Nonpharmacological Anti-inflammatory Strategies in Mental Health: Connecting Science to Clinical Practice Otsuka Pharmaceutical Development & Commercialization, Inc. Lundbeck, LLC 2017 Otsuka
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationMeasurement-based Scales in Major Depressive Disorder:
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.
More informationAntidepressant Utilization in Bipolar Disorder: What Is the Evidence?
Antidepressant Utilization in Bipolar Disorder: What Is the Evidence? 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC March 2018 MRC2.CORP.D.00336 Today s
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationDecember 2014 MRC2.CORP.D.00011
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationCo-Occurrence Of Substance Use Disorders With Mood Disorders & Psychosis
Co-Occurrence Of Substance Use Disorders With Mood Disorders & Psychosis Rebecca Roma, MD, MBA Medical Director of the Community Treatment Team Mercy Behavioral Health, Pittsburgh, PA Robert Nelson, MD
More informationDr.Rahiminejad Roozbeh Hospital TUMS
Dr.Rahiminejad Roozbeh Hospital TUMS Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications.
More informationNHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE
NHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE Associate Professor David Colquhoun 19th October 2013 University of Queensland, Wesley & Greenslopes Hospitals, Brisbane,
More informationJune 2015 MRC2.CORP.D.00030
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationStress Reactions and. Depression After. Cardiovascular Events
Stress Reactions and Depression After Cardiovascular Events Kim G. Smolderen, PhD Tilburg University, the Netherlands Saint Luke s Mid America Heart Institute, Kansas City, MO ESC Munich 2012 Disclosures
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationBecome A Supporting Organization
Become A Supporting Organization 2018 Otuska Pharmaceutical Development & Commercialization, Inc. May 2018 MRC2.CORP.X.02619 Contents 1.0 Table Of Contents 1.1-1.7 PsychU Overview 1.1-1.2 Overview 1.3
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2013 June 24; 173(12): 1150 1151. doi:10.1001/jamainternmed.2013.910. SSRI Use, Depression and Long-Term Outcomes
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More information#268 APRIL 2016 Depression is a complex heterogeneous disorder, which may need a similarly heterogeneous offer of treatment
ARE CHRONIC INFLAMMATION AND ITS METABOLIC COUNTERPART, INSULIN RESISTANCE, THE COMMON DENOMINATORS FOR ALL CHRONIC BEHAVIORAL AND NEURODEGENERATIVE DISORDERS? A REVIEW OF THE EVIDENCE PART III THE COMPLICATED
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationOpinions on the Treatment of MDD. Results of Surveys from the New York, North Carolina, and California PsychU Communities
Opinions on the Treatment of MDD Results of Surveys from the New York, North Carolina, and California PsychU Communities January 27 th, 2017 Otsuka Pharmaceutical Development & Commercialization, Inc.
More informationEvolving Psychiatry: Technology for Patient Care
Evolving Psychiatry: Technology for Patient Care David C. Mohr, PhD Director, Center for Behavioral Intervention Technologies Professor, Department of Preventive Medicine Northwestern University, Feinberg
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationDepression and CV Disease A Depressing Story. Bertram Pitt, M.D. University of Michigan School of Medicine
A Depressing Story Bertram Pitt, M.D. University of Michigan School of Medicine Davos 2011 HF affects > 5 million people in the US 15-20% of patients with HF have depression Patients with HF + depression
More informationPsychological Factors and Cardiac Risk and Impact of Exercise Training Programs A Review of Ochsner Studies
The Ochsner Journal 7:167 172, 2007 facademic Division of Ochsner Clinic Foundation Psychological Factors and Cardiac Risk and Impact of Exercise Training Programs A Review of Ochsner Studies Carl J. Lavie,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationCardiac Rehabilitation Should be Paid in Korea?
Cardiac Rehabilitation Should be Paid in Korea? Cardiac prevention & Rehabilitation Center, Heart Institute, Asan Medical Center, Seoul, Korea Jong-Young Lee, MD. NO CONFLICT OF INTEREST TO DECLARE Before
More informationThe Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine
The Heart of a Woman Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine American Heart Association Women, Heart Disease and Stroke
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abuse alcohol, aggression and, 52 53 substance, aggression and, 52 54 ACE. See Aid to Capacity Evaluation (ACE). AEDs. See Antiepileptic
More informationSummary of guideline for the. treatment of depression RANZCP CLINICAL PRACTICE GUIDELINES ASSESSMENT
RANZCP CLINICAL PRACTICE GUIDELINES Summary of guideline for the RANZCP CLINICAL PRACTICE GUIDELINES treatment of depression Pete M. Ellis, Ian B. Hickie and Don A. R. Smith for the RANZCP Clinical Practice
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationBACPR -Annual Conference London 2017
BACPR -Annual Conference London 2017 Psychological Distress in Patients with Cardiac Conditions; Developing Skills in Integrated Care and the Development of the Increasing Access to Psychological Therapies
More informationHazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke
By Michael Dixon Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any
More information7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)
University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationRecognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD)
Objectives Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) Discuss the burden of MDD on the individual and society Explore the negative impact of residual symptoms Identify
More informationLecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors
Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life
More information2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP
Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology
More informationBRAIN STIMULATION AN ALTERNATIVE TO DRUG THERAPY IN MATERNAL DEPRESSION?
BRAIN STIMULATION AN ALTERNATIVE TO DRUG THERAPY IN MATERNAL DEPRESSION? Kira Stein, MD Medical Director West Coast Life Center Sherman Oaks, California CA Maternal Mental Health Initiative - 2013 2013
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationThe life after myocardial infarction: a long quiet river?
The life after myocardial infarction: a long quiet river? Cardiac rehabilitation: for whom and how? Dr. Barnabas GELLEN MD, PhD, FESC Poitiers JESFC 2018 - Paris Conflicts of interest Speaker honoraria
More informationThe Bypassing the Blues Trial: Telephone-Delivered Collaborative Care for Treating Post-CABG Depression
The Bypassing the Blues Trial: Telephone-Delivered Collaborative Care for Treating Post-CABG Depression www.bypassingtheblues.pitt.edu Bruce L. Rollman, MD, MPH Professor of Medicine, Psychiatry, and Clinical
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationPsychosocial Issues for People with Diabetes. Richard Arakaki, M.D. Phoenix Area Diabetes Consultant June 28, 2017
Psychosocial Issues for People with Diabetes Richard Arakaki, M.D. Phoenix Area Diabetes Consultant June 28, 2017 Objectives Provide epidemiological and interventional data of DM in AI/AN and general population
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationTreatment strategies in major depression What to use when?
Treatment strategies in major depression What to use when? Michael Bauer, MD, PhD Professor and Chair of Psychiatry University Hospital Carl Gustav Carus Technische Universität Dresden Germany First-line
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More information«Πατσζαρκία και Καρδιαγγειακή Νόζος»
«Πατσζαρκία και Καρδιαγγειακή Νόζος» Δημήτρης Π. Παπαδόπουλος-FESC Clinical Assist. Professor George Washington University USA Επιμελητής Καρδιολογικής Κλινικής Π.Γ.Ν.Α. «ΛΑΪΚΟ» Υπεύθυνος Αντιυπερτασικού
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationHeart Disease. Signs and Symptoms
Heart Disease The term "heart disease" refers to several types of heart conditions. The most common type is coronary artery disease, which can cause heart attack, angina, heart failure, and arrhythmias.
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationStress and the Heart. Kim A. Poli MD, FACC Assistant Professor of Medicine Division of Cardiology, Albany Medical Center
Stress and the Heart Kim A. Poli MD, FACC Assistant Professor of Medicine Division of Cardiology, Albany Medical Center Thoughts in your mind have made you what you are, and thoughts in your mind will
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationDepression and the Role of L-methylfolate
Depression and the Role of L-methylfolate Depression is a chronic and recurrent disease affecting more than 18 million people in the United States, ranking it, along with heart disease, cancer and diabetes,
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationChapter 08. Health Screening and Risk Classification
Chapter 08 Health Screening and Risk Classification Preliminary Health Screening and Risk Classification Protocol: 1) Conduct a Preliminary Health Evaluation 2) Determine Health /Disease Risks 3) Determine
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationTaking Care: Child and Youth Mental Health TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS With appropriate treatment, more than 80% of people with depression get full relief from their symptoms
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationBright Nights: Understanding Depression
Bright Nights: Understanding Depression KEVIN SETHI, MD MARCH 18 TH, 2019 Objectives Features of Depression Facts and Myths Treatment Options Medications Neuromodulation Cognitive Behavioral Therapy Mindfulness
More informationSupplementary Online Content
Supplementary Online Content Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationPractice Matters: Screening and Referring Congregants with Major Depression
International Journal of Faith Community Nursing Volume 1 Issue 3 Article 6 October 2015 Practice Matters: Screening and Referring Congregants with Major Depression Kim Link Western Kentucky University
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationDepression, isolation, social support and cardiovascular rehabilitation in older adults
Depression, isolation, social support and cardiovascular rehabilitation in older adults B. Rauch ZAR Ludwigshafen Klinikum EuroPRevent 21 Prague some data to the actual situation Depression increases mortality
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationDSM-5 Criteria: Major Depressive Disorder
DSM-5 Criteria: Major Depressive Disorder Box 3. Major Depressive Episode: DSM-5 Diagnosis: Major Depressive Disorder Five (or more) of the following symptoms have been present during the same 2-week period
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationADHD and Adverse Health Outcomes in Adults
Thomas J. Spencer, MD This work was supported in part by a research grant from Shire (Dr. Spencer) and by the Pediatric Psychopharmacology Council Fund. Disclosures Dr. Spencer receives research support
More informationTelepsychiatry: Enhancing Access to Mental Health Care
Telepsychiatry: Enhancing Access to Mental Health Care Jonathan Evans Chief Executive Officer Safe Harbor Behavioral Health and InnovaTel Telepsychiatry, LLC., Erie, PA Meera Narasimhan, MD Associate Provost
More informationCardiovascular System and Health. Chapter 15
Cardiovascular System and Health Chapter 15 Cardiovascular Disease Leading cause of death in U.S. Claims 1 life every 43 seconds Often, the first sign is a fatal heart attack Death Rates #1 CVD #2 Cancer
More information